AstraZeneca shares sink up to 9% after Wainua misses cardiovascular endpoint in Phase 3 ATTR-CM trial with partner Ionis.
July 9, 2026 03:58 AM EDTUpdated 04:35 AM
R&DPharma
AstraZeneca sinks on unexpected heart drug trial failure
Elizabeth Cairns
Senior biopharma journalist
A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.
UK pharmaceutical company said Wainua drug did not meet goal of reducing cardiovascular deaths
AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive…
The surprising failure of AstraZeneca and Ionis in a key phase 3 tria | The surprising failure of AstraZeneca and Ionis in a key…
AstraZeneca shares fell after Wainua failed a key trial. The drug did not reduce cardiovascular deaths or heart problems. Wainua…
Ionis and AstraZeneca said Phase 3 eplontersen missed its primary ATTR-CM endpoint, while secondary measures and safety remained…
AstraZeneca, Ionis report major trial failure with heart disease drug
